ABSTRACT
Quinapyramine sulfate (QS) produces trypanocidal effects against the parasite Trypanosoma evansi but is often poorly tolerated and causes serious reactions in animals. The encapsulation of QS in chitosan-mannitol to provide sustained release would improve both the therapeutic effect of QS and the quality of life of animals treated with this formulation. QS was encapsulated into a nanoformulation prepared from chitosan, tripolyphosphate, and mannitol nanomatrix (ChQS-NPs). ChQS-NPs were well ordered in shape, with nanoparticle size, as determined by transmission electron microscopy and atomic force microscopy. Our research revealed dose-dependent effects on biosafety and DNA damage in mammalian cells treated with ChQS-NPs. ChQS-NPs were absolutely risk-free at effective as well as many times higher doses against T. evansi ChQS-NPs were effective in rabbits, as they killed the parasites, relieving the animals from the clinical symptoms of the disease. The extent of this protection was similar to that observed with the conventional drug at higher dosages (5 mg QS/kg of body weight). ChQS-NPs are safe, nontoxic, and more effective than QS and offer a promising alternative to drug delivery against surra in animal models. ChQS-NPs may be useful for the treatment of surra due to reduced dosages and frequency of administration.
Subject(s)
Biocompatible Materials/administration & dosage , Chitosan/administration & dosage , Mannitol/administration & dosage , Nanoparticles/administration & dosage , Quinolinium Compounds/pharmacology , Animals , Cell Line, Tumor , Disease Models, Animal , Drug Carriers/administration & dosage , Drug Delivery Systems/methods , HeLa Cells , Humans , Microscopy, Atomic Force/methods , Microscopy, Electron, Transmission/methods , Particle Size , Quality of Life , Rabbits , Trypanosoma/drug effectsABSTRACT
Isometamidium hydrochloride (ISMM) is an effective drug for the treatment of trypanosomosis, but it causes local and systemic toxicity. Isometamidium hydrochloride has limited therapeutic index and exhibit considerable variation in their prophylactic activities. We developed a trypanocidal nanoformulation using ISMM and polymers sodium alginate/gum acacia to enhance the efficacy of the drug at lower doses, while minimizing undesirable side effects. It was characterized by transmission electron microscopy and infrared spectroscopy for evaluation of size, morphology, functional groups, etc. In vitro cytotoxicity studies were performed by metabolic resazurin assay at different concentrations of isometamidium-loaded alginate/gum acacia nanoparticles using equine peripheral blood mononuclear cells. Hemolytic assay revealed significantly less toxicity compared to the conventional drug. The results demonstrate that the developed drug delivery module can be evaluated in suitable animal models to evaluate its potency.
Subject(s)
Alginates/chemistry , Delayed-Action Preparations/chemical synthesis , Gum Arabic/chemistry , Nanoparticles/chemistry , Phenanthridines/pharmacology , Trypanocidal Agents/pharmacology , Animals , Cell Survival/drug effects , Cells, Cultured , Delayed-Action Preparations/pharmacology , Drug Compounding , Erythrocytes/cytology , Erythrocytes/drug effects , Erythrocytes/metabolism , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Horses , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Nanoparticles/ultrastructureABSTRACT
We synthesized quinapyramine sulfate loaded-sodium alginate nanoparticles (QS-NPs) to reduce undesirable toxic effects of QS against the parasite Trypanosoma evansi, a causative agent of trypanosomosis. To determine the safety of the formulated nanoparticles, biocompatibility of QS-NPs was determined using Vero, Hela cell lines and horse erythrocytes in a dose-dependent manner. Our experiments unveiled a concentration-dependent safety/cytotoxicity (metabolic activity), genotoxicity (DNA damage, chromosomal aberrations), production of reactive oxygen species and hemolysis in QS-NPs treated cells. Annexin-V propidium iodide (PI) staining showed no massive apoptosis or necrosis. However, at very high doses (more than 300 times than the effective doses), we observed more toxicity in QS-NPs treated cells as compared to QS treated cells. QS-NPs were safe at effective trypanocidal doses and even at doses several times higher than the effective dose.
Subject(s)
Alginates/chemistry , Drug Carriers , Nanoparticles/toxicity , Quinolinium Compounds/toxicity , Trypanocidal Agents/toxicity , Animals , Cell Survival/drug effects , Chlorocebus aethiops , Chromosome Aberrations/drug effects , DNA Damage , Dose-Response Relationship, Drug , Drug Compounding , Erythrocytes/drug effects , Glucuronic Acid/chemistry , HeLa Cells , Hemolysis/drug effects , Hexuronic Acids/chemistry , Horses , Humans , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Quinolinium Compounds/chemistry , Reactive Oxygen Species/metabolism , Trypanocidal Agents/chemistry , Vero CellsABSTRACT
AIM: To reduce the dose, toxic effects and to ensure sustained release of quinapyramine sulfate (QS), a highly effective drug against Trypanosoma evansi. MATERIALS & METHODS: QS-loaded sodium alginate nanoparticles (QS-NPs) were formed by emulsion-crosslinking technology using dioctyl-sodium-sulfosuccinate and sodium alginate. The formulation was characterized for size, stability, morphology and functional groups by a zetasizer, scanning electron microscopy, atomic force microscopy, transmission electron microscopy and Fourier transform infrared spectroscopy. In vitro safety and toxicity studies were performed by metabolic assay in Vero cell lines, and in vivo efficacy was evaluated in mice. RESULTS: QS-NPs were <60 nm with 96.48% entrapment efficiency and 3.70% drug loading. The formulation showed an initial burst effect followed by slow drug release in accordance with quasi-Fickian Higuchi diffusion mechanism. QS-NPs were much less toxic and able to clear the parasite at a much lower concentration than QS. CONCLUSION: The QS-NPs synthesized are safe, less toxic and highly effective compared with QS.
Subject(s)
Alginates/chemistry , Drug Carriers/chemistry , Nanoparticles/chemistry , Quinolinium Compounds/chemistry , Sulfates/chemistry , Trypanocidal Agents/administration & dosage , Animals , Biocompatible Materials/chemistry , Chlorocebus aethiops , Cross-Linking Reagents/chemistry , Diffusion , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Kinetics , Mice , Microscopy, Atomic Force , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Models, Theoretical , Nanomedicine , Particle Size , Polymers/chemistry , Spectroscopy, Fourier Transform Infrared , Trypanosoma/drug effects , Vero CellsABSTRACT
Equine piroplasmosis is a tick-transmitted protozoan disease caused by Theileria equi and/or Babesia caballi. In the present study, we expressed a 53kDa protein from the truncated EMA-2 gene of T. equi (Indian strain) and developed EMA-2ELISA using this expressed protein. This ELISA is able to detect T. equi-specific antibodies in experimentally infected animals as early as 9 days post-infection. The assay developed was validated with the OIE recommended competitive ELISA (cELISA) on 120 serum samples and significant agreement (kappa=0.93) was observed between results of both the ELISAs which indicates suitability of EMA-2ELISA for use in sero-diagnosis. Diagnostic sensitivity and specificity of EMA-2ELISA - as compared with cELISA - were 0.97 and 0.96, respectively. Analysis of 5651 equine serum samples - collected during 2007-2012 from 12 states of India representing eight agro-climatic zones - by EMA-2ELISA revealed 32.65% seroprevalence of T. equi in India. In conclusion, the EMA-2ELISA developed using the T. equi EMA-2 recombinant protein as antigen for detecting T. equi-specific antibodies has good diagnostic potential for sero-epidemiological surveys.
Subject(s)
Antigens, Protozoan/immunology , Enzyme-Linked Immunosorbent Assay/veterinary , Horse Diseases/parasitology , Protozoan Proteins/genetics , Recombinant Proteins/immunology , Theileria/isolation & purification , Theileriasis/parasitology , Animals , Babesia/classification , Babesia/genetics , DNA/genetics , Equidae , Horse Diseases/epidemiology , Horses , India/epidemiology , Lysophospholipids , RNA, Ribosomal, 18S/genetics , Reproducibility of Results , Sensitivity and Specificity , Seroepidemiologic Studies , Theileriasis/diagnosis , Theileriasis/epidemiologyABSTRACT
Equine influenza is a contagious viral disease that affects all members of the family Equidae, i.e., horses, donkeys and mules. The authors describe the pattern of equine influenza outbreaks in a number of states of India from July 2008 to June 2009. The disease was first reported in June 2008 in Katra (Jammu and Kashmir) and spread to ten other states within a year. All outbreaks of equine influenza in the various states were confirmed by laboratory investigations (virus isolation and/or serological confirmation based on haemagglutination inhibition [HI] assays of paired samples) before declaring them as equine influenza virus-affected state(s). The virus (H3N8) was reported from various locations in the country including Katra, Mysore (Karnataka), Ahmedabad (Gujarat), Gopeshwar and Uttarkashi (Uttarakhand) and was isolated in 9- to 11-day-old embryonated chicken eggs. The virus was confirmed as H3N8 by HI assays with standard serum and amplification of full-length haemagglutinin and neuraminidase genes by reverse transcriptase-polymerase chain reaction. Serum samples (n = 4 740) of equines from 13 states in India screened by HI revealed 1074 (22.65%) samples as being positive for antibodies to equine influenza virus (H3N8).
